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Inflammatory signaling pathways are tightly regu-
lated to avoid chronic inflammation and the develop-
ment of disease. OTULIN is a deubiquitinating
enzyme that controls inflammation by cleaving linear
ubiquitin chains generated by the linear ubiquitin
chain assembly complex. Here,we show that ablation
of OTULIN in liver parenchymal cells in mice causes
severe liver disease which is characterized by liver
inflammation, hepatocyte apoptosis, and compensa-
tory hepatocyte proliferation, leading to steatohepati-
tis, fibrosis, and hepatocellular carcinoma (HCC).
Genetic ablation of Fas-associated death domain
(FADD) completely rescues and knockin expression
of kinase inactive receptor-interacting protein ki-
nase 1 (RIPK1) significantly protectsmice fromdevel-
oping liver disease, demonstrating that apoptosis of
OTULIN-deficient hepatocytes triggers disease path-
ogenesis in this model. Finally, we demonstrate that
type I interferons contribute to disease in hepato-
cyte-specific OTULIN-deficient mice. Our study re-
veals the critical importance of OTULIN in protecting
hepatocytes from death, thereby preventing the
development of chronic liver inflammation and HCC.INTRODUCTION
Liver cancer is the second most frequent cause of cancer-
related deaths and the fifth most common type of cancer world-
wide (Ringelhan et al., 2018). Of all of the primary liver cancers,
hepatocellular carcinoma (HCC) is the most frequent, respon-Cell Re
This is an open access article under the CC BY-Nsible for 80%–90% of all cases, and nearly all develop as a result
of chronic liver inflammation, inducing fibrosis, cirrhosis, and
finally HCC. There is clear evidence that cell death represents
a basic biological process in liver cancer, wherein hepatocyte
death induces compensatory hepatocyte regeneration, chronic
liver inflammation, and activation of non-parenchymal cells, pro-
moting liver fibrosis and tumorigenesis (Luedde and Schwabe,
2011; Kondylis and Pasparakis, 2019).
Tumor necrosis factor (TNF) is a major inflammatory cytokine,
capable of inducing inflammatory gene expression, but also of
triggering cell death. Many studies have shown that optimal
regulation of TNF signaling is essential to maintain liver homeo-
stasis and prevent liver inflammation and inflammation-induced
HCC (Luedde et al., 2014). Inflammatory signaling, such as by
TNF, is heavily controlled by ubiquitination, a posttranslational
modification of proteins (Iwai et al., 2014). Sensing of TNF by
TNF receptor 1 (TNFR1) initiates the assembly of a receptor-
proximal complex, known as complex I, which activates the
mitogen-activated protein kinase (MAPK) and nuclear factor-
kB (NF-kB) signaling pathways (Ting and Bertrand, 2016). The
initial binding of TNFR1-associated death domain protein
(TRADD) and receptor-interacting protein kinase 1 (RIPK1) to
the receptor allows the subsequent recruitment of TNF recep-
tor-associated factor 2 (TRAF2) and of the E3 ubiquitin ligases
cellular inhibitors of apoptosis 1 and 2 (cIAP1/2). The K63-ubiq-
uitin chains generated by cIAP1/2 serve as docking stations for
the adaptor proteins TAB2/3 and for the recruitment of the kinase
TAK1, which subsequently activate the MAPK signaling path-
ways. These K63-ubiquitin chains also assist in recruiting the
linear ubiquitin chain assembly complex (LUBAC, composed of
HOIL-1, HOIP, and SHARPIN), which further conjugates com-
plex I components with linear-ubiquitin chains. The adaptor pro-
tein NEMO binds to these linear chains and brings the kinases
IKKa and IKKb to the complex, thereby allowing activation of
the NF-kB pathway. NEMO recruitment to the complex alsoports 30, 2237–2247, February 18, 2020 ª 2020 The Authors. 2237
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
enables activation of the kinases TBK1/IKKε, whichmay regulate
NF-kB activation (Clark et al., 2011; Lafont et al., 2018; Xu et al.,
2018). Upon activation, theMAPK andNF-kB pathways drive the
expression of a large set of genes, including pro-inflammatory
genes (Ting and Bertrand, 2016).
The linear-ubiquitin chains generated by the LUBAC in the
TNFR1 pathway are therefore essential for the NF-kB-depen-
dent expression of pro-inflammatory genes, but they were
also shown to play a double and crucial role in preventing
TNF cytotoxicity. Apart from pro-inflammatory molecules, the
activation of NF-kB also leads to the transcriptional upregula-
tion of anti-apoptotic proteins, which protect cells from RIPK1
kinase-independent apoptosis (Wang et al., 2008). In addition,
the linear ubiquitin-dependent phosphorylation of RIPK1 by
IKKa/b and TBK1/IKKε was shown to protect cells from RIPK1
kinase-dependent apoptosis (Dondelinger et al., 2015, 2019;
Lafont et al., 2018; Xu et al., 2018; Ting and Bertrand, 2016).
Consequently, when these protective brakes are compromised,
such as following LUBAC deficiency (Peltzer et al., 2014, 2018;
Priem et al., 2019), activated TRADD and RIPK1 dissociate from
complex I, and respectively induce RIPK1 kinase-independent
and -dependent apoptotic cascades through association with
Fas-associated death domain (FADD) protein and procas-
pase-8 to form the cytosolic death-inducing complex II.
Necroptosis occurs when caspase-8 activation is blocked and
involves RIPK1 kinase-dependent recruitment of RIPK3 and
mixed-lineage kinase domain-like protein (MLKL) to complex
II, inducing strong inflammatory responses (Ting and Bertrand,
2016). Hence, LUBAC activity is essential in preventing
apoptotic and necroptotic cell death, and HOIP- and HOIL-1-
deficient mice die during development (Peltzer et al., 2014,
2018).
Ubiquitination is a reversible process, and the deubiquitinating
(DUB) enzyme OTULIN (OTU deubiquitinase with linear linkage
specificity, also known as Fam105b or Gumby) exclusively
cleaves the linear ubiquitin chains generated by LUBAC, and
hence critically controls inflammatory and cell death responses
(Keusekotten et al., 2013; Rivkin et al., 2013). Accordingly,
mice harboring a point mutation abolishing the ability of OTULIN
to bind ubiquitin (‘‘Gumby’’ mice) or knockin mice expressing a
catalytically inactive variant of OTULIN die in utero due to exces-
sive inflammatory cell death (Rivkin et al., 2013; Heger et al.,
2018). However, mice with inducible OTULIN deficiency were
shown to be viable and develop a severe inflammatory disease
(Damgaard et al., 2016), resembling an autoinflammatory syn-
drome in humans carrying homozygous hypomorphic OTULIN
mutations, called OTULIN-related autoinflammatory syndrome
(ORAS, also known as otulipenia) (Zhou et al., 2016; Damgaard
et al., 2016, 2019; Nabavi et al., 2019). Although OTULIN was
originally shown to negatively regulate LUBAC activity, its defi-
ciency does not induce LUBAC hyperactivity, as expected, but
rather suppresses its function. OTULIN-, HOIP-, and HOIL-1-
deficient mice have very similar phenotypes displaying embry-
onic lethality due to uncontrolled cell death. Together, these
data showed that OTULIN promotes rather than counteracts
LUBAC signaling by preventing LUBAC autoubiquitination
through the removal of linear ubiquitin chains from LUBAC
(Heger et al., 2018).2238 Cell Reports 30, 2237–2247, February 18, 2020In light of the reported function of OTULIN in regulating both
TNF-induced NF-kB signaling and cell death (Keusekotten
et al., 2013; Damgaard et al., 2016, 2019; Heger et al., 2018),
we questioned the role of OTULIN in liver (patho)physiology.
For this, we generated OTULIN conditional knockout (KO) mice
that are specifically deficient for OTULIN in liver parenchymal
cells. Thesemice spontaneously develop chronic liver inflamma-
tion, fibrosis, and HCCs, illustrating the importance of OTULIN in
normal liver tissue homeostasis. Chronic liver pathology results
from the hypersensitivity of OTULIN-deficient hepatocytes to
spontaneous FADD- and RIPK1 kinase activity-dependent
apoptosis, which triggers compensatory hepatocyte prolifera-
tion and inflammation. Type I interferon (IFN) signaling also con-
tributes to liver pathology in OTULIN-deficient mice. Together,
these studies establish OTULIN as a crucial hepatoprotective
factor.
RESULTS
Development of a Severe Liver Pathology in Hepatocyte-
Specific OTULIN KO Mice
Otulin-targeted ES cells (Otulintm1a(EUCOMM)Hmgu) were used to
generate chimeric mice that transmitted the targeted allele to
their offspring. Mice homozygous for the LoxP-flanked Otulin
allele (OtulinFL/FL) express normal levels of OTULIN and develop
normally (data not shown). Deletion of the LoxP-flanked Otulin
alleles through the expression of a ubiquitously expressed Cre
recombinase leads to a loss of OTULIN protein, as shown in
mouse embryonic fibroblasts (MEFs) (Figure S1A). In agreement
with previous studies (Rivkin et al., 2013; Damgaard et al., 2016;
Heger et al., 2018), full-body OTULIN KO mice are not viable
(Figure S1B), preventing further study. To study the role of
OTULIN in hepatocytes and in liver physiology and pathology,
we crossed the OtulinFL/FL mice with a transgenic mouse line
that expresses Cre under the control of the liver-specific albu-
min/a-fetoprotein (AFP) promoter/enhancer (Alfp-Cre), which
mediates efficient Cre recombination in liver parenchymal cells
(Kellendonk et al., 2000; Figures S1C and S1D). Hepatocyte-
specific OTULIN KO (OtulinFL/FL/Alfp-Cre, liver parenchymal
cell-specific OTULIN KO [OTULINLPC-KO]) mice were born with
normal Mendelian segregation. Immunoblot analysis of liver
protein extracts revealed efficient ablation of OTULIN in the
livers of OTULINLPC-KO mice (Figure 1A). Residual OTULIN
expression in these livers can be attributed to nonparenchymal
liver cells that are not targeted by the Alfp-Cre allele.
The dissection of livers from 8- to 10-week-old OTULINLPC-KO
mice revealed the presence of a severe liver phenotype. All
OTULINLPC-KO livers displayed hepatomegaly and an aberrant
liver architecture with the presence of numerous small but
macroscopically visible nodules, in contrast to littermate control
mice that did not show any overt liver pathology (Figures 1B,
S2A, and S2B). At the same time, OTULINLPC-KO mice displayed
elevated levels of the liver-specific enzymes aspartate transam-
inase (AST), alanine transaminase (ALT), and alkaline phospha-
tase (ALP), indicative of liver damage (Figure 1C), and also
displayed hyperbilirubinemia, indicative of cholestasis (Fig-
ure 1C). Histological analysis confirmed a severe chronic inflam-
matory liver disease characterized by immune cell infiltration,
Figure 1. Development of a Severe Liver Phenotype in OTULINLPC-KO Mice
(A) Western blot analysis for OTULIN expression in total liver lysates from a control wild-type (WT) and OTULINLPC-KO littermate mouse. Anti-tubulin immuno-
blotting was used as loading control. *, unspecific. Data are representative of three independent experiments.
(B) Macroscopic pictures of representative livers from a 10-week-old WT and OTULINLPC-KO littermate mouse.
(C) Serum ALT, AST, ALP, and bilirubin levels of control (WT; n = 11) and OTULINLPC-KO (n = 7) mice. Data are presented as mean ± SEM. ***p < 0.001; ****p <
0.0001.
(D) Representative H&E-stained liver section from 10-week-oldWT andOTULINLPC-KOmice demonstrating the loss of normal hepatic architecture andmultifocal,
lobular infiltration of mononuclear cells in the livers of OTULINLPC-KO mice. Scale bar, 50 mm.
(E) Relative mRNA levels of Il6, Il1b,Mcp1, and Rantes in total liver lysates from 10-week-old OTULINLPC-KO mice (n = 8) and control (WT, n = 11) mice. Data are
presented as mean ± SEM. **p < 0.01; ***p < 0.001; ****p < 0.0001.
(F andG) Cytokeratin 19 (CK19) (F) and Sirius Red (G) staining on liver sections from 10-week-oldWT andOTULINLPC-KOmice demonstrating oval cell hyperplasia
and fibrosis in OTULINLPC-KO livers. Scale bar, 200 mm.
(H) Representative oil red O-stained liver cryosections from 10-week-old WT and OTULINLPC-KO mice. Scale bar, 200 mm.
(I) Representative H&E-stained liver section showing early well-differentiated HCC in 6-month-old OTULINLPC-KO mice. T, tumor. Scale bar, 200 mm.proliferation of oval cells, and hypertrophy of hepatocytes (Fig-
ures S2C–S2H). In addition, the OTULIN-deficient livers demon-
strated multifocal cell death of individual hepatocytes and an
increase in the number of mitotic figures and nuclear sizes (poly-
ploidy) (Figures 1D and S2E–S2H). Flow cytometry analysis
further suggested an inflammatory phenotype with an increased
proportion of monocytes in OTULIN-deficient livers (Figure S3A–
S3D). In addition, this analysis identified a significant proportion
of Clec4F+Tim4 Kupffer cells (KCs) in OTULINLPC-KO livers.
Typically, the presence of Tim4 KCs suggests KC death and
their subsequent replacement from circulating monocytes,
which only gain Tim4 expression with time (Scott et al., 2016;
Figures S3A–S3D). The increased expression of pro-inflamma-
tory cytokines and chemokines (Il6, Il1b, Rantes, and Mcp1)could also be demonstrated in the OTULIN-deficient liver lysates
(Figure 1E). Sirius Red staining, Tgfb1 mRNA expression, and
CK19 immunostaining confirmed the presence of fibrosis, asso-
ciated with oval cell hyperplasia, in the livers of OTULINLPC-KO
mice (Figures 1F, 1G, and S3E–S3G). Finally, OTULIN-deficient
livers showed increased lipid deposition in hepatocytes (Figures
1H and S3H). In contrast to OTULINLPC-KO mice, liver sections
from wild-type mice showed a normal hepatic parenchyma
and no signs of inflammation, lipid deposition, or fibrosis (Figures
1D–1H, S2, and S3).
The liver phenotype of OTULINLPC-KO mice, characterized by
chronic inflammation and fibrosis, resembles non-alcoholic
steatohepatitis (NASH) in humans and represents a risk factor
for the development of HCC (Sherman, 2005). To evaluateCell Reports 30, 2237–2247, February 18, 2020 2239
Figure 2. OTULIN Suppresses Linear Ubiquitination and Cell Death in Liver Parenchymal Cells
(A) Western blot analysis for the expression of OTULIN and LUBAC proteins in liver lysates from WT and OTULINLPC-KO mice. Anti-tubulin immunoblotting was
used as a loading control. Data are representative of two independent experiments.
(B) M1 chains were immunoprecipitated from whole liver cell lysates from untreated OTULINLPC-KO and control littermate mice (WT) using GST-UBANs. Protein
levels were determined by immunoblotting. Data are representative of two independent experiments.
(C) Representative images of liver sections from 10-week-old OTULINLPC-KO and control (WT) mice after immunostaining for cleaved caspase-3. Scale bar,
200 mm.
(D) Quantification of the number of caspase-3+ cells. Data are presented as mean ± SEM, n = 5 mice per genotype. **p < 0.01.
(E) Western blot analysis for expression of full-length (FL) and cleaved (Cl) caspase-3 in liver lysates from OTULINLPC-KO and control littermate mice (WT). Anti-
actin immunoblotting was used as a loading control. Data are representative of three independent experiments.
(F) Serum ALT and AST levels of OTULINLPC-KO (n = 3) and control littermate mice (WT, n = 3) either injected or not injected with 5 mg mouse TNF for the indicated
time points. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ****p < 0.0001.
(G) Cleaved caspase-3 staining on liver sections from OTULINLPC-KO mice and control WT littermate mice injected with TNF for 3 h. Scale bar, 200 mm.
(H) Western blot analysis for OTULIN, and FL and Cl caspase-8 and -3 expression in liver lysates from OTULINLPC-KO and control littermate mice (WT) either
injected or not injected with 5 mg mouse TNF for 5 h. Data are representative of two independent experiments.
(I) Caspase activity assayed on liver tissue homogenates ofWT (n = 3) andOTULINLPC-KO littermate (n = 3)mice either injected or not injectedwith TNF for 5 h. Data
are presented as mean ± SEM. ****p < 0.0001. Statistical differences were determined by two-way ANOVA.
(J) Western blot analysis for OTULIN, IkBa, phosphorylated IkBa, JNK, phosphorylated JNK, p38, and phosphorylated p38 in liver lysates fromOTULINLPC-KO and
control littermate mice (WT) either injected or not injected with 5 mg mouse TNF for the indicated time points. Anti-actin immunoblotting was used as a loading
control. Data are representative of two independent experiments.whether OTULINLPC-KO lesions represent pre-neoplastic lesions,
which may develop at later stages into HCC, livers from
6-month-old OTULINLPC-KO mice were dissected. All of the
OTULINLPC-KO mice displayed a severe liver phenotype with
the presence of multiple nodules (Figure S4A), which were not
detected in the livers of control littermate mice. Histology
demonstrated the presence of early well-differentiated HCC
in 3 of 8 KO cases (37.5%) (Figure 1I), while the other 5 KO
livers displayed diffuse and severe pre-neoplastic lesions remi-
niscent of HCC. Malignancy was further confirmed in young
OTULINLPC-KOmice by increasedRNA levels of several oncofetal
HCC marker genes, such as AFP and connective tissue growth
factor (CTGF), as well as of hepatic stem cell marker genes,2240 Cell Reports 30, 2237–2247, February 18, 2020such as glypican 3 (GPC-3) and CD133 (Figures S4B and S4C).
By the age of 1 year, all of theOTULINLPC-KOmice had developed
severe liver pathology displaying multiple neoplastic lesions,
ranging from adenoma to HCC (Figures S4D–S4G).
OTULIN Deletion Leads to Accumulation of Linear
Ubiquitin Chains, but Paradoxically Causes
Spontaneous Hepatocyte Apoptosis
LUBAC-mediated linear ubiquitination plays an important role in
the activation of the NF-kB signaling pathway and in protecting
cells from death (Peltzer et al., 2014, 2018). OTULIN is reported
to counteract LUBAC activity by removing the linear chains con-
jugated to LUBAC substrates, which include TNFR1, NEMO,
Figure 3. Enhanced Hepatocyte Proliferation in OTULIN-Deficient
Livers
(A) Representative images of liver sections from 10-week-old OTULINLPC-KO
mice and control (WT) mice after Ki67 immunostaining for proliferating cells.
Scale bar, 200 mm.
(B) Quantification of the number of Ki67+ cells. Data are presented as mean ±
SEM, n = 5 mice per genotype. ***p < 0.001.
(C) Relative mRNA expression of Cyclin D1 in total liver lysates from 10-week-
old OTULINLPC-KO mice (n = 12) and control (WT, n = 11) mice. Data are pre-
sented as mean ± SEM. ***p < 0.001.
(D) Liver protein extracts from 10-week-old OTULINLPC-KO mice and control
(WT) mice were subjected to western blotting using antibodies detecting
OTULIN, cyclin D1, and PCNA. Anti-tubulin immunoblotting was used as a
loading control. Data are representative of three independent experiments.RIPK1, RIPK2, and MyD88 (Hrdinka and Gyrd-Hansen, 2017). In
accordance, OTULIN deficiency was shown to cause hyper-
ubiquitination of signaling proteins, leading to NF-kB hyper-acti-
vation and inflammatory signaling (Hrdinka and Gyrd-Hansen,
2017). A recent report, however, showed that OTULIN promotes
rather than counteracts LUBAC activity by preventing its autou-
biquitination, and that knockin mice expressing DUB-inactive
OTULIN resemble LUBAC-deficient mice and die at midgesta-
tion due to pro-inflammatory cell death (Heger et al., 2018). We
demonstrated that the specific deletion of OTULIN in hepato-
cytes resulted in the reduced expression of HOIP and SHARPIN
(Figure 2A), as previously reported in other cell types (Heger
et al., 2018; Damgaard et al., 2016, 2019), including MEFs (Fig-
ure S1A). Despite the reduced LUBAC expression levels, anal-
ysis of linear ubiquitination by specific UBANpulldowns revealed
the massive accumulation of linear polyubiquitin in liver lysates
of OTULIN-deficient mice (Figure 2B). The accumulation of
linear chains caused by OTULIN deletion correlated withincreased apoptosis of hepatocytes. In contrast to control livers,
OTULINLPC-KO livers showed dispersed and numerous cleaved
caspase-3 and TUNEL+ cells, indicative of apoptosis induction
(Figures 2C, 2D, S5A, and S5B). The detection of cleaved
caspase-8 and -3 in OTULIN-deficient liver lysates further
demonstrated that OTULIN deficiency sensitizes hepatocytes
to caspase-dependent extrinsic apoptosis (Figures 2B and 2E).
To better understand the role of OTULIN in protecting hepato-
cytes from apoptosis, we evaluated the consequences of its defi-
ciency in the TNFR1 signaling pathway. For this, OTULINLPC-KO
mice and control littermate mice were injected with a normally
sublethal dose of recombinant mouse TNF (5 mg/20 g body
weight). In contrast to control mice, which only showed a modest
drop in body temperature after injection with TNF, OTULINLPC-KO
mice displayed severe hypothermia (Figure S5C) and high levels
of liver-specific AST and ALT enzymes in their serum, indicative
of massive liver damage (Figure 2F). OTULINLPC-KO livers dis-
played numerous cleaved caspase-3+ hepatocytes in response
to the TNF challenge (Figure 2G). Hepatocyte apoptosis was
further confirmed by the presence of cleaved caspase-8 and -3
in the liver lysates (Figure 2H) and by a caspase-3-specific enzy-
matic DEVD-activity assay (Figure 2I). Finally, the sensitization to
apoptosis was associated with enhanced TNF-induced JNK acti-
vation and a slight defect in TNF-induced NF-kB activation, as
monitored by reduced IkBa degradation, in OTULINLPC-KO livers
(Figure 2J). Also, in vitro, enhanced JNK phosphorylation and
reduced NF-kB activation could be observed after TNF stimula-
tion of primary hepatocytes isolated from OTULINLPC-KO mice
(Figure S5D).
These data demonstrate the importance of OTULIN in re-
stricting M1 ubiquitination in hepatocytes and identify OTULIN
as an essential protein protecting mice from hepatocyte
apoptosis and acute liver failure. These results also demon-
strate that despite the spontaneous accumulation of linear
polyubiquitin in OTULIN-deficient livers, signaling to NF-kB
by TNF is compromised, which may provide a molecular expla-
nation for the spontaneous apoptosis of OTULIN-deficient
hepatocytes.
Hepatocyte Apoptosis Is Accompanied by
Compensatory Hepatocyte Proliferation in OTULIN-
Deficient Livers
The liver has remarkable regenerative capacity, and hepatocytes
start massively proliferating following hepatic loss to restore liver
function and mass (Luedde et al., 2014). Since hepatocyte
apoptosis in OTULIN-deficient mice may be the driving force
triggering hepatocyte proliferation favoring hepatocarcinogene-
sis, we next assessed liver proliferation in OTULINLPC-KO mice.
Hepatocyte apoptosis in OTULINLPC-KO mice was accompanied
by excessive liver cell proliferation, as demonstrated by the
increased number of Ki67+ cells (Figures 3A and 3B). In agree-
ment, expression of the cell-cycle markers cyclin D1 and prolif-
erating cell nuclear antigen (PCNA) was strongly enhanced in
liver lysates of OTULINLPC-KO mice (Figures 3C and 3D). These
data underline the correlation between hepatocyte cell death
and proliferation and suggest that the severe liver pathology
in OTULINLPC-KO mice develops as a result of continuous hepa-
tocyte apoptosis and compensatory hepatocyte proliferation,Cell Reports 30, 2237–2247, February 18, 2020 2241
Figure 4. FADD Deficiency or Absence of RIPK1 Kinase Activity Protects OTULINLPC-KO Mice from Developing Liver Pathology
(A) Macroscopic pictures of representative livers from a 10-week-old OTULINLPC-KO, OTULINLPC-KO/RIPK1D138N/D138N, and OTULIN/FADDLPC-KO mouse. Scale
bar, 2 mm.
(B) Serum ALT, AST, and ALP levels in control (WT, n = 49), OTULINLPC-KO (n = 22), OTULINLPC-KO/RIPK1D138N/D138N (n = 11), and OTULIN/FADDLPC-KO (n = 18)
mice. Data are presented as mean ± SEM. ***p < 0.001; ****p < 0.0001.
(C) Representative H&E, Cl caspase-3, and Ki67-stained liver section from 10-week-old OTULINLPC-KO, OTULINLPC-KO/RIPK1D138N/D138N, and OTULIN/
FADDLPC-KO mice. Scale bar H&E, 100 mm; cleaved caspase-3 and Ki67, 200 mm.
(D) Relative mRNA expression of Tgfb1 in total liver lysates from 10-week-old control (WT, n = 7), OTULINLPC-KO (n = 6), OTULINLPC-KO/RIPK1D138N/D138N (n = 6),
and OTULIN/FADDLPC-KO (n = 8) mice. Data are presented as mean ± SEM. *p < 0.05.
(E) Quantification of the number of cleaved caspase-3+ cells in liver sections from control (WT, n = 6), OTULINLPC-KO (n = 5), OTULINLPC-KO/RIPK1D138N/D138N
(n = 7), and OTULIN/FADDLPC-KO (n = 8) mice. Data are presented as mean ± SEM. ****p < 0.0001.
(F) Quantification of the number of Ki67+ cells in liver sections from control (WT, n = 9), OTULINLPC-KO (n = 6), OTULINLPC-KO/RIPK1D138N/D138N (n = 8), andOTULIN/
FADDLPC-KO (n = 7) mice. Data are presented as mean ± SEM. ***p < 0.001; ****p < 0.0001.promoting the development of chronic hepatitis, fibrosis, and
eventually HCC.
FADD and RIPK1 Kinase Activity-Dependent Apoptosis
Drives Hepatocyte Death and Liver Pathology in
OTULINLPC-KO Mice
Since OTULIN was previously shown to be essential to prevent
TNF-dependent systemic inflammation in humans and in mice
(Zhou et al., 2016; Damgaard et al., 2016, 2019), we next ad-
dressed the specific role of TNF in triggering the spontaneous
death of OTULIN-deficient hepatocytes, leading to the develop-
ment of spontaneous liver pathology in OTULINLPC-KO mice. For
this, we generated TNF-deficient OTULINLPC-KO mice. The ge-
netic deletion of Tnf did not prevent spontaneous liver pathology
in OTULINLPC-KO mice (Figure S6A). Although 10-week-old
OTULINLPC-KO/TNFKO mice had lower levels of serum ALT, AST,
and ALP compared to the levels seen in OTULINLPC-KO mice (Fig-
ure S6B), histological analysis of liver tissue revealed that the
additional deletion of TNF did not significantly reduce immune
cell infiltration or the numbers of caspase-3+ hepatocytes (Figures
S6C–S6E). Similarly, KO of TNFR1 in all of the cells did not protect2242 Cell Reports 30, 2237–2247, February 18, 2020OTULINLPC-KO mice from developing liver disease (Figures S6A–
S6E). These results demonstrate that TNF signaling does not
drive chronic liver damage in OTULINLPC-KO mice.
Previous studies have demonstrated that the protective role of
linear ubiquitination against RIPK1 kinase-dependent and -inde-
pendent FADD-mediated apoptosis is not limited to TNFR1
signaling (Lafont et al., 2017; Taraborrelli et al., 2018), suggesting
conserved regulatory mechanisms downstream of various death
receptors. Since RIPK1 has already been implicated in liver
pathology by regulating hepatocyte death (Kondylis and Paspar-
akis, 2019), we evaluated the presence and consequence
of RIPK1 kinase-dependent apoptosis of hepatocytes in our
OTULINLPC-KO mice. To do so, we crossed OTULINLPC-KO mice
to knockin mice expressing a kinase-inactive RIPK1-D138N
mutant (Polykratis et al., 2014). Ten-week-old OTULINLPC-KO/
RIPK1D138N/D138N mice demonstrated slightly reduced liver
pathology, but showed significantly reduced serum ALT,
AST, and ALP levels and reduced Tgfb1 expression compared
to OTULINLPC-KO mice (Figures 4A, 4B, and 4D). Although the
livers from OTULINLPC-KO/RIPK1D138N/D138N mice still revealed
aberrant tissue architecture, significantly reduced numbers of
apoptotic hepatocytes but not of proliferating hepatocytes could
be observed in the livers from OTULINLPC-KO/RIPK1D138N/D138N
mice compared to OTULINLPC-KO mice (Figures 4C–4E).
Because RIPK1 kinase activity can induce both FADD-
dependent apoptosis and RIPK3/MLKL-dependent necroptosis
(Pasparakis and Vandenabeele, 2015), we next evaluated
the occurrence of MLKL-dependent hepatocyte necroptosis.
OTULINLPC-KOmicewere crossed tomice with a floxedMlkl allele
(Murphy et al., 2013), generating mice lacking both OTULIN and
MLKL specifically in liver parenchymal cells. MLKL deficiency
could, however, not prevent liver pathology in OTULINLPC-KO
mice, as shown by liver histology and detection of liver damage
in OTULIN/MLKLLPC-KO mice (Figure S6), arguing against a role
for MLKL-driven necroptosis in the OTULINLPC-KO pathology.
To confirm that hepatocyte apoptosis is responsible for the
development of liver pathology in OTULINLPC-KO mice, we next
generated OTULINLPC-KO mice lacking FADD specifically in liver
parenchymal cells by crossing the OTULINLPC-KO line with mice
having a floxed Fadd allele (FADDFL/FL) (Mc Guire et al., 2010),
thereby preventing both RIPK1 kinase-dependent and -indepen-
dent FADD-mediated apoptosis. In contrast to OTULINLPC-KO
mice, all of which developed severe liver pathology, OTULIN/
FADDLPC-KO mice had a completely normal tissue architecture
and did not display liver damage, as detected by tissue histol-
ogy; by serum analysis of ALT, AST, and ALP levels; and by
the expression of Tgfb1 reminiscent of liver fibrosis (Figures
4A–4D). Even in aged 45-week-old mice, no liver pathology
could be observed in OTULIN/FADDLPC-KO mice (Figure S7). In
agreement, no hepatocyte cell death, shown by cleaved cas-
pase-3 detection in liver tissue sections, could be detected in
livers from OTULIN/FADDLPC-KO mice (Figures 4C and 4E). In
addition to rescuing hepatocyte death, FADD deficiency in-
hibited the increased proliferation observed in the livers of
OTULINLPC-KO mice, as shown by the reduced Ki67 staining in
liver lysates from OTULIN/FADDLPC-KO mice (Figures 4C and
4F). This demonstrates that the increased hepatocyte prolifera-
tion and inflammation in the livers of OTULINLPC-KOmice are sec-
ondary responses to the apoptosis of OTULIN-deficient hepato-
cytes. These data show that liver disease in OTULINLPC-KO mice
develops as a consequence of FADD-dependent apoptosis,
partially driven by RIPK1 kinase activity, but not necroptosis, of
OTULIN-deficient hepatocytes.
Finally, since inflammation-induced liver injury is often associ-
ated with increased intestinal permeability and bacterial translo-
cation to the liver via the portal vein (Seki and Schnabl, 2012), we
assessed the importance of MyD88-dependent signaling for
the development of liver pathology in OTULINLPC-KO mice. Ten-
week-old OTULINLPC-KO/MyD88KOmicewere, however, not pro-
tected from developing liver disease, and all of them exhibited
similar increased serum ALT, AST, and ALP levels compared
with OTULINLPC-KO mice (Figures S6A and S6B). Also, on histol-
ogy, no differences in immune cell infiltration, hepatocyte cell
death, and proliferation could be observed (Figures S6C–S6E).
IFN Signaling Contributes to the Liver Pathology in
Hepatocyte-Specific OTULIN KO Mice
The liver phenotype of OTULINLPC-KO mice was associated
with a significant upregulation of inflammatory gene expression,including the expression of IFN response genes, which were re-
verted to baseline levels in the FADD-deficient genetic back-
ground (Figures 1E, 5A, and S8). The serum from OTULINLPC-KO
mice also contained elevated amounts of the IFN-inducible
chemokine Cxcl10 (Figure 5B). This suggests that OTULIN may
also be important in suppressing the production of type I IFNs,
as suggested by recent studies demonstrating the promotion of
IFN-a receptor (IFNAR) signaling in conditions in which OTULIN
or LUBAC signaling is impaired (Heger et al., 2018; Peltzer et al.,
2018). To investigate whether type I IFN signaling contributes to
the development of liver pathology in OTULINLPC-KO mice, we
generated OTULINLPC-KO mice lacking the IFNAR1 (M€uller et al.,
1994). Ten-week-old OTULINLPC-KO/IFNAR1KO mice demon-
strated reduced liver pathology and showed significantly reduced
AST, ALT, and ALP levels compared to OTULINLPC-KO mice (Fig-
ures 5C and 5D). In addition, significantly reduced numbers of
apoptotic hepatocytes but not of proliferating hepatocytes could
be observed in livers from OTULINLPC-KO/IFNAR1KO mice
compared to those from OTULINLPC-KO mice (Figures 5E–5G).
These data demonstrate that type I IFNs are produced in
OTULIN-deficient livers and critically contribute to the severe liver
phenotype in OTULINLPC-KO mice.
DISCUSSION
The incidence of hepatitis and HCC has risen in Western coun-
tries, most probably because of changes in dietary habits
causing metabolic stress, the metabolic syndrome, and non-
alcoholic fatty liver disease (NAFLD). HCC develops as a result
of chronic liver inflammation and is mostly diagnosed at
advanced stages, with very limited treatment options. Hence,
early and sustained suppression of chronic liver damage is key
to reducing the risk of developing HCC (Ringelhan et al., 2018).
Here, we have demonstrated the spontaneous TNF-independent
but FADD-dependent apoptosis of hepatocytes as the crucial
event driving liver inflammation, fibrosis, and HCC in hepato-
cyte-specific OTULIN-deficient mice. Our study also demon-
strated that RIPK3-MLKL-dependent hepatocyte necroptosis
is not involved in the pathology of OTULINLPC-KO mice, likely
due to the absence of RIPK3 expression in hepatocytes, as pre-
viously demonstrated (Dara et al., 2015; Krishna-Subramanian
et al., 2019). OTULIN/MLKLLPC-KO mice, lacking both OTULIN
and MLKL only in the hepatocytes, seem to display an even
worse liver phenotype compared to OTULINLPC-KO mice. This
would suggest that MLKL-dependent necroptosis, eventually
through a pathway independent of RIPK3, would protect
OTULIN-deficient hepatocytes from death by apoptosis. A
recent study demonstrated that the suppression of necroptosis
in hepatocytes could promote hepatocyte apoptosis, favoring
the development of HCC (Seehawer et al., 2018). This observa-
tion suggested that hepatocyte necroptosis generates a liver
cytokine microenvironment that promotes the development of
intrahepatic cholangiocarcinoma and not HCC from oncogeni-
cally transformed hepatic cells (Seehawer et al., 2018). More
studies will be needed to investigate this further.
The protective role of LUBAC-mediated linear ubiquitination is
well established downstream of TNFR1. On the one hand, it pro-
motes the transcriptional upregulation of anti-apoptotic proteinsCell Reports 30, 2237–2247, February 18, 2020 2243
Figure 5. Interferon Signaling Contributes to Liver Pathology in OTULINLPC-KO Mice
(A) Relative mRNA expression of Cxcl10, Ifit1, Ifit3, and Isg15 in total liver lysates from 10-week-old control (WT, n = 7), OTULINLPC-KO (n = 6), and OTULIN/
FADDLPC-KO (n = 8) mice. Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
(B) Serum Cxcl10 levels in 10-week-old control (WT, n = 5), OTULINLPC-KO (n = 6), and OTULIN/FADDLPC-KO (n = 6) mice. Data are presented as mean ± SEM.
**p < 0.01.
(C) Macroscopic pictures of representative livers from 10-week-old control (WT), OTULINLPC-KO, and OTULINLPC-KO/IFNAR1KO mice. Scale bar, 5 mm.
(D) Serum ALT, AST, and ALP levels in control (WT, n = 57), OTULINLPC-KO (n = 22), and OTULINLPC-KO/IFNAR1KO (n = 12) mice. Data are presented as mean ±
SEM. ***p < 0.001; ****p < 0.0001.
(E) Representative H&E, cleaved caspase-3, and Ki67-stained liver section from 10-week-old control (WT), OTULINLPC-KO, and OTULINLPC-KO/IFNAR1KO mice.
Scale bar H&E, 100 mm; cleaved caspase-3 and Ki67, 200 mm.
(F) Quantification of the number of Cl caspase-3+ cells in liver sections from control (WT, n = 4), OTULINLPC-KO (n = 3), and OTULINLPC-KO/IFNARKO mice (n = 6).
Data are presented as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001.
(G) Quantification of the number of Ki67+ cells in liver sections from control (WT, n = 4), OTULINLPC-KO (n = 3), and OTULINLPC-KO/IFNARKO mice (n = 6). Data are
presented as mean ± SEM. **p < 0.01; ***p < 0.001.by NF-kB, which protects cells from RIPK1 kinase-independent
apoptosis (Wang et al., 2008). On the other hand, it allows the
phosphorylation of RIPK1 by IKKa/b and TBK1/IKKε, which was
shown to protect cells from RIPK1 kinase-dependent apoptosis
(Dondelinger et al., 2015, 2019; Ting and Bertrand, 2016; Lafont
et al., 2018; Xu et al., 2018). While several studies have reported
the importance of proper TNF signaling for the maintenance of
liver homeostasis and to prevent liver inflammation and inflamma-
tion-induced HCC (Luedde et al., 2014), our study did not identify
TNF as a driving cytokine in the liver pathology of OTULINLPC-KO
mice. The molecular mechanism by which linear ubiquitination
protects cells from death may, however, not be limited to
TNFR1 but instead be conserved between death receptors.
LUBAC was also shown to protect cells from RIPK1 kinase-
dependent and -independent FADD-mediated apoptosis down-
stream of other TNFR superfamily members (Lafont et al., 2017;2244 Cell Reports 30, 2237–2247, February 18, 2020Taraborrelli et al., 2018). In accordance with this notion, we found
that the transgenic expression of a kinase-inactive RIPK1D138N
mutant could significantly ameliorate but not fully rescue the
liver disease. This indicates that hepatocyte apoptosis in
OTULINLPC-KO mice is FADD/caspase-8 dependent and partially
drivenbyRIPK1kinaseactivity.Despite themassiveaccumulation
of linear polyubiquitin, signaling to NF-kB by TNF was compro-
mised in OTULIN-deficient hepatocytes, suggesting that OTULIN
deficiency also affects proper signaling to NF-kB downstream
of the receptor that triggers apoptosis in OTULINLPC-KO mice.
Therefore, a defect in the NF-kB-mediated upregulation of cyto-
protectivemechanisms inOTULIN-deficient hepatocytesmay ac-
count for the RIPK1 kinase-independent hepatocyte apoptosis,
while inappropriate regulation of RIPK1 by IKKs may account for
the RIPK1 kinase-dependent hepatocyte apoptosis, together
inducing liver inflammation and a partial liver pathology.
Since IFNAR1 deficiency protects OTULINLPC-KO mice, at
least partially, from developing severe liver disease, we further
demonstrate an important contribution of type I IFNs to the
phenotype of OTULINLPC-KO mice. This observation suggests
that OTULIN may also suppress the pathways that are respon-
sible for the production of IFNs, either indirectly by preventing
overall inflammation or by direct control of IFN production. In
that context, FADD and RIPK1 have been identified as being
implicated in an immune defense pathway against intracellular
double-stranded RNA (dsRNA) (Balachandran et al., 2004; Mi-
challet et al., 2008; Rajput et al., 2011; Ingram et al., 2019).
Further studies are required to identify the pathway(s) regulated
by OTULIN driving type I IFN production.
Our results using hepatocyte-specific OTULIN-deficient mice
also confirm the importance of linear ubiquitination and its
regulation by OTULIN for protection against hepatocyte
apoptosis and liver inflammation, which are in agreement with
a previous study demonstrating the importance of LUBAC-
mediated linear ubiquitination for liver physiology preventing
hepatocyte apoptosis, hepatitis, and HCC development (Shi-
mizu et al., 2017).
ORAS (OTULIN-related autoinflammatory syndrome) is a
potentially fatal, rare, early-onset autoinflammatory disease
caused by homozygous hypomorphic mutations in the human
OTULIN gene (Zhou et al., 2016; Damgaard et al., 2016, 2019;
Nabavi et al., 2019). ORAS patients develop neonatal-onset sys-
temic inflammation, high fevers, dermatitis and panniculitis, diar-
rhea, and arthritis. However, thus far, no clinical manifestations
of liver disease in ORAS patients have been documented nor
have OTULIN mutations been identified in the livers of HCC pa-
tients. Analysis of the TCGA (The Cancer Genome Atlas) micro-
array dataset (https://www.cancer.gov/about-nci/organization/
ccg/research/structural-genomics/tcga) indicated an increase
rather than a decrease in OTULIN mRNA levels in HCC tissues
(n = 374) compared with normal liver tissue (n = 50) (p =
5.91e12 comparing all tumor samples; p = 3.55e6 comparing
50 paired tumor samples). While these results are intriguing, it
remains unknown whether OTULIN expression in these liver
samples is relevant for HCC or simply a consequence of liver
pathology.
In conclusion, with our studies, we identified OTULIN as a crit-
ical regulator of liver homeostasis by protecting the liver paren-
chymal cells from death by apoptosis, which could drive liver
inflammation, fibrosis, and eventually liver cancer, similar to
what has been demonstrated for NEMO (Luedde et al., 2007;
Kondylis et al., 2015). Blockade of hepatocyte cell death may
thus have therapeutic potential for patients suffering from
chronic inflammatory liver diseases. Also, hepatocyte-specific
OTULIN-deficient mice may serve as a novel model to study
NAFLD and HCC and help to develop new treatments for the
diagnosis of or therapeutic intervention in patients suffering
from inflammation-induced liver pathologies risking the develop-
ment of HCC.
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Antibodies
cleaved caspase 3 Cell Signaling Technology Cat# 9661; RRID:AB_2341188
Ki67 Cell Signaling Technology Cat# 12202; RRID:AB_2620142
goat anti-rabbit Agilent Cat# E0432; RRID:AB_2313609
Otulin Cell Signaling Technology Cat# 14127; RRID:AB_2576213
A20 Santa Cruz Biotechnology Cat# sc-166692; RRID:AB_2204516
caspase 3 Cell Signaling Technology Cat# 9662; RRID:AB_331439
JNK BD Bioscience Cat# 554285; RRID:AB_395344
P-JNK Millipore Cat# PS1019-100UL; RRID:AB_10696844
IkBa Santa Cruz Biotechnology Cat# sc-371; RRID:AB_2235952
P-IkBa Cell Signaling Technology Cat# 9246; RRID:AB_2267145
Sharpin Proteintech Cat# 14626-1-AP; RRID:AB_2187734
Cyclin D1 Abcam Cat# ab190564
Tubulin Sigma-Aldrich Cat# T4026; RRID:AB_477577
PCNA Novus Cat# NB500-106; RRID:AB_2252058
b-actin Santa Cruz Biotechnology Cat# sc-47778 HRP; RRID:AB_2714189
anti-rabbit-IgG-HRP GE Healthcare Cat# GENA934; RRID:AB_2722659
anti-mouse-IgG-HRP GE Healthcare Cat# NA931; RRID:AB_772210
anti-goat-IgG-HRP Santa Cruz Biotechnology Cat# sc-2354; RRID:AB_628490
CD26-FITC BD Biosciences Cat# 559652; RRID:AB_397295
CD172a-BB630P BD Bioscience custom conjugate
Tim4-Percp-eFluor710 Thermo Fisher Scientific Cat# 46-5866-82; RRID:AB_2573781
Clec4F-unconjugated R and D Systems Cat# AF2784; RRID:AB_2081339
Goat IgG-AF647 Thermo Fisher Scientific Cat# A-21447; RRID:AB_2535864
Live/dead dye – APCeFluor780 eBioscience cat#65-0865-18
Ly6C-eFluor450 Thermo Fisher Scientific Cat# 48-5932-82; RRID:AB_10805519
CD45-BV510 BioLegend Cat# 103138; RRID:AB_2563061
CD11b-BV605 BD Biosciences Cat# 563015; RRID:AB_2737951
CD64-BV711 BioLegend Cat# 139311; RRID:AB_256384
F4/80-BV786 BioLegend Cat# 123141; RRID:AB_2563667
XCR1-BV650 BioLegend Cat# 148220; RRID:AB_2566410
SiglecF-BUV395 BD Biosciences Cat# 740280; RRID:AB_2740019
Ly6G-BUV563 BD Biosciences cat#612921
MHCII-BUV805 BD Biosciences custom conjugate
CD11c-PE-eFluor610 Thermo Fisher Scientific Cat# 61-0114-82; RRID:AB_2574530
CD3 Tonbo Biosciences Cat# 70-0031; RRID:AB_2621472
CD19 Thermo Fisher Scientific Cat# 35-0193-82; RRID:AB_891395
B220 BD Biosciences Cat# 553091; RRID:AB_394621
NK1.1-PE-Cy5 BioLegend Cat# 108716; RRID:AB_493590
Ripk1 Cell Signaling Technology Cat# 3493; RRID:AB_2305314
cleaved caspase 8 Cell Signaling Technology Cat# 9429; RRID:AB_2068300
caspase 8 Abnova Corporation Cat# MAB3429; RRID:AB_10629060
Anti-Linear Ubiquitin Antibody, clone LUB9 Millipore cat#MABS451
goat anti-rabbit polyclonal IgG biotin Agilent cat# E043201; RRID:AB_2313609
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CK19 Lammer lab n/a
hoip Damgaard lab n/a
hoil-1 Walczak lab n/a
Chemicals, Peptides, and Recombinant Proteins
TRIzol reagent Thermo Fisher Scientific cat#15596026
mTNF This paper n/a
Collagenase A Sigma-Aldrich cat#11088793001
GST-UBAN Ivan Dikic lab n/a
DNase Roche cat#04 536 282 001
DMEM GIBCO cat# 41965-062
DMEM F12 GIBCO cat# 31330-038
non essential aminoacids Lonza cat#BE13-114E
L-glutamin Lonza cat# BE17-605F
bovine collagen 1 Nutacon n/a
Sodium pyruvate Sigma-Aldrich cat# S-8636
Penicillin-Streptomycin GIBCO cat#15140-122
fetal calf serum Bodinco n/a
Complete, EDTA-free Protease Inhibitor
Cocktail Tablets
Roche cat#11873580001
PhosStop Roche cat# 04906837001
Antigen retrieval buffer Dako cat# S-203130
hydrogen peroxide 30% Sigma-Aldrich cat# H-1009
Hematoxylin Mayer’s Sigma cat# 51275-500ml
Entellan Merck cat# 107961
Neg 50 Kryo-Medium Thermo Fisher Scientific cat# 6506
Direct Red 80 Sigma cat# 365548
Ac-DEVD-MCA PeptaNova cat# 3171-V
Critical Commercial Assays
Aurum Total RNA Isolation Mini Kit BioRad cat# 7326820
Sensifast cDNA Synthesis Kit Bioline cat#BIO-65054
SensiFAST SYBR No-ROX Kit GeC Biotech cat# CSA-01190
Vectastain ELITE ABC Kit Standard Vector Laboratories cat# PK-6100
ImmPACT DAB Peroxidase (HRP) Substrate Vector Laboratories cat# SK-4105
Western Lightning Plus ECL Perkin Elmer cat# NEL101001EA
TUNEL Millipore cat#17-141
Trygliceride colorimetric assay kit Cayman chemical cat#10010303
Deposited Data
TCGA database n/a https://www.cancer.gov/about-nci/organization/
ccg/research/structural-genomics/tcga
Experimental Models: Cell Lines
mouse: primary hepatocytes this paper n/a
OTULINKO MEFs this paper n/a
Experimental Models: Organisms/Strains
mouse: OTULINFL this paper n/a
mouse: Alfp Cre Kellendonk et al., 2000 n/a
mouse: MlklFL Murphy et al., 2013 n/a
mouse: FaddFL Mc Guire al., 2010 n/a
mouse: Ripk1D138N Polykratis et al., 2014 n/a
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mouse: MyD88/ Adachi et al., 1998 n/a
mouse: Tnf/ Pasparakis et al., 1996 n/a
mouse: Tnfr1/ Pfeffer et al., 1993 n/a
mouse: Ifnar/ M€uller et al., 1994 n/a
Oligonucleotides
qPCR primers see Table S1 n/a n/a
Software and Algorithms
ZEN (blue edition) Zeiss https://www.zeiss.com/microscopy/int/products/
microscope-software/zen.html
FlowJo.10 n/a https://www.flowjo.com/
GraphPad Prism 8 n/a https://www.graphpad.com/
Fluostar Omega BMG Labtech https://www.bmglabtech.com/fluostar-omega/
Other
Axioscan Zeiss n/a
BDSymphony BD Biosciences n/a
LightCycler 480 II Roche n/a
Amersham Imager 600 GE Healthcare n/aLEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents may be directed to Geert van Loo (Lead Contact; geert.vanloo@irc.
vib-ugent.be). Resources and reagents generated in this study are available from the Lead Contact but may require a Materials
Transfer Agreement to be signed.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animals
The following mouse lines were used: Alfp-Cre (Kellendonk et al., 2000), FaddFL (Mc Guire al., 2010), MlklFL (Murphy et al., 2013),
Ripk1D138N (Polykratis et al., 2014), Myd88/ (Adachi et al., 1998), Tnf/ (Pasparakis et al., 1996), Tnfr1/ (Pfeffer et al., 1993)
and Ifnar1/ (M€uller et al., 1994). Otulin floxed mice were generated from Otulin/Fam105btm1a C57BL/6 embryonic stem (ES)
cells (generated by the European Mouse Mutagenesis (EUCOMM) Programme). All experiments on mice were conducted according
to institutional, national and European animal regulations. Animal protocols were approved by the ethics committee of Ghent
University. Mice were housed in individually ventilated cages at the VIB Center for Inflammation Research, in a specific pathogen-
free animal facility. Mice were housed in temperature- and humidity-controlled conditions at 21C and 60% relative humidity,
14/10 h light/darkness. Further, a wooden stick and nesting material (tissues) were present as environmental enrichment. Food
and regular drinking water were provided ad libitum for all experiments. All experiments were performed on 10-52-week old mice.
All mice had a C57BL/6 genetic background. Both sexes were used in this study and littermates were used as controls in all
experiments.
Cells
MEFs were grown in complete DMEM (DMEM (GIBCO) medium supplemented with 10% fetal calf serum (Bodinco), 1% penicillin/
streptomycin (GIBCO), 1% L-Glutamine (Lonza), 0.4% sodium-pyruvate (Sigma) and 1% non-essential amino acids (Lonza)). MEFs
were grown at 37C, 5%CO2 and 5%O2. The sex of theMEFs cells was never determined as these cells were isolated from embryos.
Primary hepatocytes were grown on plates coated with collagen (Nutacon) in DMEM F12 (GIBCO) supplemented with 10% fetal calf
serum (Bodinco) and 1% penicillin/streptomycin (GIBCO). Primary hepatocytes were grown at 37C and 5% CO2. Primary hepato-
cytes were isolated both from male and female mice.
METHOD DETAILS
Mice
The following mouse lines were used: Alfp-Cre (Kellendonk et al., 2000), FaddFL (Mc Guire al., 2010), MlklFL (Murphy et al., 2013),
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and Ifnar1/ (M€uller et al., 1994). All alleles were maintained on a C57BL/6 genetic background. Mice were housed in individually
ventilated cages at the VIB Center for Inflammation Research, in a specific pathogen-free animal facility. All experiments on mice
were conducted according to institutional, national and European animal regulations. Animal protocols were approved by the ethics
committee of Ghent University.
Generation of hepatocyte-specific OTULIN knockout mice
C57BL/6 embryonic stem (ES) cells with an Otulin/Fam105btm1a allele were generated by the European Mouse Mutagenesis
(EUCOMM) Programme using a ‘knockout-first with conditional potential’ gene targeting cassette, and used to generate mice
bearing a neomycin-LacZ cassette and a loxP-flanked exon 3 of Otulin. For this, the targeted ES cell clone was injected into
3.5-day blastocysts and transferred to the uteri of pseudopregnant foster mothers. Male chimeras werematedwith C57BL/6 females
to obtain germline transmission of the Otulin floxed allele (still containing the neomycine selection cassette, OtulinNFL). The Frt-
flanked neomycin-LacZ cassette was removed by crossingOtulinNFLmicewith a Flp-deleter strain (Rodrı´guez et al., 2000) generating
an Otulin floxed allele (OtulinFL). OtulinFL/FL mice were crossed to Alfp-Cre transgenic mice (Kellendonk et al., 2000) to generate liver
parenchymal cell-specific OTULIN knockout (OtulinLPC-KO) mice (Figure S1C, D).
Isolation and immortalization of mouse embryonic fibroblasts (MEFs)
Otulin+/mice were generated by crossing chimeras transmitting the OtulinFL genotype with Cre-deleter mice. MEFs were prepared
from E10.5 Otulin+/+, Otulin+/ and Otulin/ embryos, and immortalized through serial passaging and frozen in liquid nitrogen.
Isolation of liver cells for immune profiling
The protocol for the isolation of liver cells was adapted fromMederacke et al. (2015) as previously described (Bonnardel et al., 2019).
Briefly, after retrograde cannulation, livers were first perfused with an EGTA-containing solution for 1–2 min following by a perfusion
with 0.2 mg/ml collagenase A-containing solution for 5 min (6 ml/min). Livers were minced and incubated for 20 min with 0.4 mg/ml
Collagenase A and 10 U/ml DNase in a water bath at 37C. All subsequent procedures were performed at 4C. After filtration with a
100 mm mesh filter, the cell suspensions were centrifuged at 400 g for 7 min and re-suspended in 2 mL of red blood lysis buffer for
3 min. Suspensions were washed in PBS and further filtered on a 40 mmmesh filter and centrifuged twice for 1 min at 50 g resulting in
an hepatocytes-enriched fraction (pellet) and a leukocytes/LSECs/HSCs-enriched fraction (supernatant). Both fractions were further
centrifuged at 400 g for 7 min before proceeding with FACS staining. After staining cells were analyzed on a BDSymphony and
resulting data were analyzed using FlowJo Software. Following antibodies were used: CD26-FITC (BD, Cat no: 559652), CD172a-
BB630P (BD, Custom conjugate), Tim4-Percp-eFluor710 (Thermo Fischer, Cat no: 46-5866-82), Clec4F-unconjugated (R&D sys-
tems, Cat no: AF2784), Goat IgG-AF647 (Thermo Fischer, Cat no: A-21447), Fixable Live/dead dye – APCeFluor780, Ly6C-eFluor450
(eBioscience – Cat no: 48-5932-82), CD45-BV510 (Biolegend, Cat no: 103138), CD11b-BV605 (BD, Cat no: 563015), CD64-BV711
(Biolegend, Cat no: 139311), F4/80-BV786 (Biolegend, Cat no: 123141), XCR1-BV650 (Biolegend, Cat no: 148220), SiglecF-BUV395
(BD, Cat no: 740280), Ly6G-BUV563 (BD, Cat no: 612921), MHCII-BUV805 (BD, custom conjugate), CD11c-PE-eFluor610
(eBioscience, Cat no: 61-0114-82), Lineage markers – CD3 (TONB55-0031-U100, Tonbo Biosciences), CD19 (15-1093-83,
eBioscience), B220 (553091, BD), NK1.1-PE-Cy5 (108716, Biolegend).
Primary hepatocytes
Hepatocytes were isolated as described above (Isolation of liver cells for immune profiling). Cells were seeded and cultured in DMEM
F12 with 10% fetal calf serum (Bodinco) and 1% penicillin/streptomycin (GIBCO). Cells were left untreated or stimulated with mTNF
(20 ng/mL, VIB Protein Service Facility) for the indicated time points.
Western blot analysis
Cells and liver tissue were homogenized using E1A lysis buffer (50 mM HEPES pH7.6; 250 mM NaCl; 5 mM EDTA; 0.5% NP40) and
RIPA (50 mM Tris-HCl, pH 7.6; 1 mM EDTA; 150 mM NaCl; 1% NP-40; 0.5% sodiumdeoxycholate; 0.1% SDS) buffer respectively
containing protease inhibitors (Roche) and phosphatase inhibitors (Sigma), denaturated in 1 x Laemmli buffer (50 mM Tris-HCl
pH8.2; 2% SDS; 10% glycerol; 0.005% BFB; 5% b-mercapto-ethanol) and boiled for 10 min at 95C. 50 mg of liver lysates and 20
ug of cell lysates were separated by SDS-polyacrylamide gel electrophoresis (PAGE), transferred to nitrocellulose and analyzed
by immunoblotting. Membranes were probed with antibodies against OTULIN (1:1000, Cell Signaling Technology), A20 (1:1000,
Santa Cruz Biotechnologies), caspase-3 (full length and cleaved) (1:1000, Cell Signaling Technology), cleaved caspase-8 (1:1000,
Cell Signaling Technology), caspase-8 (1:1000, Abnova), JNK (1:1000, BD Bioscience), phospho-JNK (1:1000, Sigma-Aldrich),
IkBa (1:1000, Santa Cruz Biotechnologies), phospho-IkBa (1:1000, Cell Signaling Technology), HOIL-1 (1:2000, kind gift of Dr. Hen-
ningWalczak, UCL London), HOIP (1:1000, kind gift of Dr. Rune Damgaard, MRCCambridge), Sharpin (1:1000, Proteintech, 1:1000),
PCNA (1:1000, Novus), cyclin-D1 (1:1000, Abcam), Ripk1 (1:2000, Cell Signaling Technology), linear ubiquitin (1:2500, Millipore),
tubulin (1: 1000, Sigma-Aldrich) and actin-HRP (1:10000, MP Biomedicals). As secondary antibodies, HRP coupled anti-rabbit-
HRP, anti-mouse-HRP and anti-goat-HRP were used (1:2500, Amersham) and detection was done by chemiluminescence (Western
Lightning Plus ECL, Perkin Elmer) using the Amersham Imager 600 (GE Healthcare).Cell Reports 30, 2237–2247.e1–e6, February 18, 2020 e4
Immunoprecipitation
Recombinant GST-UBAN was produced in BL21(DE3) cells. In brief, BL21(DE3) cells were transformed with the plasmid encoding
GST-UBAN and protein expression was induced with 0.5 M IPTG. After 4 h, cells were collected and lysed in lysis buffer (20 mM Tris-
HCl pH 7.5, 10 mM EDTA, 5mM EGTA, 150 mM NaCl, 1mM DTT supplemented with phosphatase and protease inhibitor cocktail
tablets (Roche Diagnostics)), sonicated and cleared by centrifugation. After centrifugation, Triton X-100 (0.5% final concentration)
was added to the supernatant, which was then transferred onto prewashed glutathione beads and left rotating for 2 h at 4C. After
incubation, the beads were centrifuged, washed twice with washing buffer (20 mM Tris-HCl pH 7.5, 10 mM EDTA, 150 mM NaCl,
0.5%Triton X-100) and resuspended in resuspension buffer (20mMTris-HCl pH 7.5, 0.1% b-mercaptoethanol, 0.05% sodiumazide),
ready to be used. Cell lysates from total liver tissue were prepared as described before, protein concentration was determined and
5 mg protein lysate was incubated overnight with GST-UBAN-containing glutathione beads. The next day, the beads were washed
three times in RIPA lysis buffer (150 mM NaCl, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS, 10 mM Tris-HCl pH 8 supple-
mented with phosphatase and protease inhibitor cocktail tablets (Roche Diagnostics)). Beads were then resuspended in 60 mL
1x laemmli buffer for direct analysis.
Cell death assay
Liver tissues were lysed in caspase lysis buffer (1% NP-40, 200 mM NaCl, 10 mM Tris-HCl pH 7, 5 mM EDTA, 10% glycerol, freshly
supplemented with Complete, EDTA-free Protease Inhibitor Cocktail Tablets (Roche)) and volume was adjusted to reach a protein
concentration of 2 mg/ml. 20 mg of cell lysate was added to 140 ml of CFS buffer (10 mM HEPES pH 7.5, 220 mM mannitol, 68 mM
sucrose, 2 mM NaCl, 2 mM MgCl2, 2.5 mM KH2PO4, supplemented with 10 mM DTT and Complete, EDTA-free Protease Inhibitor
Cocktail Tablets (Roche)) containing 50 mMacetyl-Asp-Glu-Val-Asp-aminomethylcoumarin (Ac-DEVD-amc, PeptaNova). Caspase-3
activation wasmeasured at intervals of 3 min using a Fluostar Omega fluorescence plate reader, with an excitation filter of 360 nm, an
emission filter of 460 nm, gains set at 900, 10 flashes per well and orbital averaging with a diameter of 3 mm.
Liver injury
Mice were injected i.p. with a sublethal dose of mouse TNF (5 mg mouse TNF/20 g body weight). E. coli-derived recombinant mTNF
had a specific activity of 9.463 107 IU/mg, andwas produced and purified to homogeneity in our laboratory with endotoxin levels not
exceeding 1 ng/mg protein. Mice were euthanized after 2.5 h for histological analysis. Serum alkaline phosphatase (ALP), alanine
transaminase (ALT), aspartate transaminase (AST) and bilirubin levels were measured in the Laboratory of Clinical Biology of the
University Hospital Gent, according to standard procedures.
Histology
Livers were dissected and fixed in 4% paraformaldehyde and embedded in paraffin. Sections were stained with Hematoxylin/Eosin
(HE) or with specific stains or antibodies. For immunohistochemistry, following dewaxing, slides were incubated in antigen retrieval
solution (Dako), boiled for 20min in a PickCell cooking unit and cooled down for 3 h. Endogenous peroxidase activity was blocked by
incubating the slides in 3% wv H2O2 (Sigma). The blocking buffer contains 0.2% goat serum, 0.5% Fish skin gelatin and 2% BSA in
PBS. Subsequently slides were incubated with primary antibodies overnight at 4C: anti-cleaved caspase 3 (1:300, Cell Signaling),
anti-Ki67 (1:1000, Cell Signaling) or rabbit anti-CK19 (1:600, kindly provided by Wout Lamers, AMC, Amsterdam). Next, the slides
were incubated with biotin coupled goat anti-rabbit (1:500, Dako). Subsequently, slides were incubated in ABC solution (Vectastain
ELITE ABC Kit Standard, Vector Laboratories). Peroxidase activity was detected by adding diaminobutyric acid (DAB) substrate
(ImmPACT DAB Peroxidase (HRP) Substrate, Vector Laboratories), and slides were counterstained with hematoxylin (Sigma),
dehydrated and mounted with Entellan (Merck). TUNEL kit (Millipore) was used to visualize apoptotic cells, according to manufac-
turer’s instructions. The pictures were taken with the Zeiss slide scanner. For Sirus red staining, slides were dried overnight at 55C,
nuclei were stained with Weigert’s hematoxylin (Sigma) and then slides were incubated with Sirius red solution, made by 0,5 g Sirius
Red (Direct Red 80, Sigma) and 500 mL saturated aqueous solution of picric acid (1.3% in water, Sigma). For Oil Red O staining, liver
samples were fixed in 4% PFA for 2 h and incubated in 30% sucrose overnight after which they were frozen in OCT cryostat embed-
ding medium (Neg50 Kryo-Medium, Thermo Fisher Scientific). Coupes were fixed in 4%PFA and subsequently incubated in 100%
propylene glycol, Oil Red O (at 60C) and 85% propylene glycol. The sections were counterstained with hematoxylin (Sigma).
Histological scoring
Histological diagnosis was performed on HE-stained slides using standard histopathological analysis based on cellular morphology
of mouse liver lesions (Thoolen et al., 2010). The main lesions observed were classified and eventually scored (0: none/minimal; 1:
mild; 2:moderate; 3: severe) as: foci of necrosis, portal, and lobular inflammation/immune cells infiltration, anisocytosis, and aniso-
karyosis (respectively, variations of cellular and nuclear size and shape), pigmented macrophages, intranuclear pseudoinclusions,
foci of vacuolar changes, lobular dysplasia, hepatocellular hypertrophy, foci of cellular alteration (FCA), adenoma, hepatocellular car-
cinoma (HCC). Oval cell proliferation was evaluated based on a grading system applied to stage precirrhotic/cirrhotic lesions in
mouse liver (Kleiner et al., 2005; H€ubscher, 2006) as following: STAGE 1: perisinusoidal or periportal (1A: mild, zone3, perinusoidal;
1B: moderate, zone 3, perisinusoidal; 1C: portal/periportal only); STAGE 2: perisinusoidal and portal/periportal; STAGE 3: bridging
fibrosis/oval cell proliferation; STAGE 4: cirrhosis. The number of mitotic figures and apoptotic cells was evaluated in 5 randomlye5 Cell Reports 30, 2237–2247.e1–e6, February 18, 2020
selected HPF (high power fields, 40X). Differentiation between dysplastic nodules (DNs) and early HCC was based on criteria pub-
lished for the analysis of human liver (Kondo, 2009; Park, 2011; Schlageter et al., 2014). Due to the difficulty in distinguishing early
HCC from DNs in some of the liver samples, a further category indicated with ‘‘indiscernible’’ nodular lesion has been introduced,
characterized by a transitional histological appearance in between the two lesions. The immunohistochemistry for Ki67 and CK19
was also evaluated in order to distinguish between these two lesions. The following criteria have been applied to analyze the
nodules: 1) higher cellularity (usually 2 times that of the surrounding hepatic parenchyma in HCC); 2) plate thickness and/or
pseudoglandular (microacinar) structures (typical of HCC); 3) stromal invasion: well differentiated tumor cells invade the fibrous tissue
of portal tracts with lack of ductular reaction (evident by the analysis of CK19 stained slides, typical of HCC); 4) presence of portal
tracts (evident by CK19 IHC, present in varying number, usually reduced in HCC; may be present in HNs and DNs); 5) higher number
of Ki67-positive hepatocytes (evaluated by IHC, compared to the surrounding parenchyma); 6) vacuolar changes (common in HCC,
may be present in DNs); 7) lack of distinct demarcation (more typical of HCC); 8) cellular pleomorphism and loss of normal lobular
architecture (present in both DNs and HCC); 9) compression (typical of adenoma when compression of adjacent normal hepatocytes
is seen at least on two quadrants). Ki67, Caspase 3 and TUNEL stained slides were evaluated under a microscope, counting the
number of positive nuclei in ten randomly selected high power fields, 40X. The total number of positive nuclei for each was divided
by 10 to obtain the index. Positive cells within inflammatory foci and areas of oval cell hyperplasia/fibrosis were excluded from
the count. The extent of the hepatic parenchyma stained with CK19 and Sirius red was evaluated by semiquantitative grading
(0: none/minimal; 1: mild; 2: moderate; 3: severe).
Cxcl10 detection
Serum was isolated from adult mice and Cxcl10 was measured by Bio-Plex (Biorad, Pro Mouse Chemokine IP-10/CXCL10 Set),
according to manufacturer’s instructions.
Quantitative real-time PCR
Total RNA was isolated using TRIzol reagent (Invitrogen) and Aurum Total RNA Isolation Mini Kit (Biorad), according to manufac-
turer’s instructions. Synthesis of cDNA was performed using Sensifast cDNA Synthesis Kit (Bioline) according to the manufacturer’s
instructions. cDNA was amplified on quantitative PCR in a total volume of 5 ml with SensiFAST SYBRNo-ROX Kit (Bioline) and spe-
cific primers on a LightCycler 480 (Roche). The reactionswere performed in triplicates. Mouse-specific primers that were used for this
study can be found in Table S1, related to STAR Methods.
TCGA database analysis
Liver cancer gene expression profiles in the TCGA database (https://www.cancer.gov/about-nci/organization/ccg/research/
structural-genomics/tcga) were downloaded using the R package TCGA-assembler, including 424 HCC and liver samples of
mRNA expression profiles. Gene expression values were plotted as log2(CPM) values.
QUANTIFICATION AND STATISTICAL ANALYSIS
Results are expressed as the mean ± SEM, with n the number of mice. Normality tests (Kolmogorov-Smirnov) were performed to
check for normal distribution of the data. As all data were normally distribute, parametric tests were performed to check the statistical
significance between different groups. Statistical significance betweenWT and OTULINLPC-KO was assessed using an unpaired two-
sample Student t-Test, unless stated otherwise. Statistical significance between OTULINLPC-KO and the different genetic crosses
was assessed using a one-way ANOVA test, followed by Tukey’s multiple comparison test. The analysis was performed with Prism
software (V8). Statistical details can be found in the figure legends.
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